{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:30:19Z","timestamp":1787725819684,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10147-025-02933-9","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:17:15Z","timestamp":1764681435000},"page":"160-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of first-line immuno-oncology combinations with molecular targeted therapy in patients with advanced renal cell carcinoma undergoing hemodialysis: a real-world multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8154-6616","authenticated-orcid":false,"given":"Kosuke","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Minato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Kiyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaji","family":"Kumagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Tatarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2933_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/01.ju.0000177489.98031.54","volume":"174","author":"S Satoh","year":"2005","unstructured":"Satoh S, Tsuchiya N, Habuchi T et al (2005) Renal cell and transitional cell carcinoma in a Japanese population undergoing maintenance dialysis. J Urol 174:1749\u20131753. https:\/\/doi.org\/10.1097\/01.ju.0000177489.98031.54","journal-title":"J Urol"},{"key":"2933_CR2","doi-asserted-by":"publisher","first-page":"c11","DOI":"10.1159\/000077590","volume":"97","author":"I Ishikawa","year":"2004","unstructured":"Ishikawa I (2004) Present status of renal cell carcinoma in dialysis patients in Japan: questionnaire study in 2002. Nephron Clin Pract 97:c11\u2013c16. https:\/\/doi.org\/10.1159\/000077590","journal-title":"Nephron Clin Pract"},{"key":"2933_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2559.1993.tb00091.x","volume":"22","author":"I Ishikawa","year":"1993","unstructured":"Ishikawa I, Kovacs G (1993) High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 22:135\u2013139. https:\/\/doi.org\/10.1111\/j.1365-2559.1993.tb00091.x","journal-title":"Histopathology"},{"key":"2933_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12253-016-0179-x","volume":"23","author":"L Kuthi","year":"2017","unstructured":"Kuthi L, Jenei A, Hajdu A et al (2017) Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients. Pathol Oncol Res 23:689\u2013698. https:\/\/doi.org\/10.1007\/s12253-016-0179-x","journal-title":"Pathol Oncol Res"},{"key":"2933_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/pin.12718","volume":"68","author":"T Kondo","year":"2018","unstructured":"Kondo T, Sasa N, Yamada H et al (2018) Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: central pathology results according to the 2016 WHO classification in a multi-institutional study. Pathol Int 68:543\u2013549. https:\/\/doi.org\/10.1111\/pin.12718","journal-title":"Pathol Int"},{"key":"2933_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.eururo.2011.02.035","volume":"60","author":"Y Neuzillet","year":"2011","unstructured":"Neuzillet Y, Tillou X, Mathieu R et al (2011) Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 60:366\u2013373. https:\/\/doi.org\/10.1016\/j.eururo.2011.02.035","journal-title":"Eur Urol"},{"key":"2933_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.pas.0000185382.80844.b1","volume":"30","author":"SK Tickoo","year":"2006","unstructured":"Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141\u2013153. https:\/\/doi.org\/10.1097\/01.pas.0000185382.80844.b1","journal-title":"Am J Surg Pathol"},{"key":"2933_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/iju.15314","volume":"31","author":"H Ishihara","year":"2024","unstructured":"Ishihara H, Ikeda T, Fukuda H et al (2024) Renal cell carcinoma outcomes in end-stage renal disease: a 40-year study from two Japanese institutions. Int J Urol 31:73\u201381. https:\/\/doi.org\/10.1111\/iju.15314","journal-title":"Int J Urol"},{"key":"2933_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"key":"2933_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134. https:\/\/doi.org\/10.1056\/NEJMoa060655","journal-title":"N Engl J Med"},{"key":"2933_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722\u2013731. https:\/\/doi.org\/10.1056\/NEJMoa1303989","journal-title":"N Engl J Med"},{"key":"2933_CR12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281. https:\/\/doi.org\/10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"key":"2933_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"2933_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384:829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"2933_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"2933_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"2933_CR17","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"2933_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","volume":"76","author":"IA Strohbehn","year":"2020","unstructured":"Strohbehn IA, Lee M, Seethapathy H et al (2020) Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series. Am J Kidney Dis 76:299\u2013302. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.451","journal-title":"Am J Kidney Dis"},{"key":"2933_CR19","doi-asserted-by":"publisher","first-page":"e903","DOI":"10.1016\/j.clgc.2019.06.009","volume":"17","author":"MG Vitale","year":"2019","unstructured":"Vitale MG, Baldessari C, Milella M et al (2019) Immunotherapy in dialysis-dependent cancer patients: our experience in patients with metastatic renal cell carcinoma and a review of the literature. Clin Genitourin Cancer 17:e903\u2013e908. https:\/\/doi.org\/10.1016\/j.clgc.2019.06.009","journal-title":"Clin Genitourin Cancer"},{"key":"2933_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2933_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11523-023-00956-8","volume":"18","author":"H Ishihara","year":"2023","unstructured":"Ishihara H, Nemoto Y, Nakamura K et al (2023) Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: a real-world retrospective multi-institutional study. Target Oncol 18:209\u2013220. https:\/\/doi.org\/10.1007\/s11523-023-00956-8","journal-title":"Target Oncol"},{"key":"2933_CR22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/jjco\/hyu117","volume":"44","author":"E Ikezawa","year":"2014","unstructured":"Ikezawa E, Kondo T, Hashimoto Y et al (2014) Clinical symptoms predict poor overall survival in chronic-dialysis patients with renal cell carcinoma associated with end-stage renal disease. Jpn J Clin Oncol 44:1096\u20131100. https:\/\/doi.org\/10.1093\/jjco\/hyu117","journal-title":"Jpn J Clin Oncol"},{"key":"2933_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/1753-0407.12957","volume":"11","author":"H Yang","year":"2019","unstructured":"Yang H, Yin K, Wang Y et al (2019) Pre-existing type 2 diabetes is an adverse prognostic factor in patients with renal cell carcinoma. J Diabetes 11:993\u20131001. https:\/\/doi.org\/10.1111\/1753-0407.12957","journal-title":"J Diabetes"},{"key":"2933_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/0284186X.2021.2005255","volume":"61","author":"TA Horsb\u00f8l","year":"2022","unstructured":"Horsb\u00f8l TA, Dalton SO, Christensen J et al (2022) Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. Acta Oncol 61:58\u201363. https:\/\/doi.org\/10.1080\/0284186X.2021.2005255","journal-title":"Acta Oncol"},{"key":"2933_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/sdi.12888","volume":"33","author":"N Hayami","year":"2020","unstructured":"Hayami N, Ubara Y, Okaneya T et al (2020) Outcome of renal cell carcinoma in patients on dialysis compared to non-dialysis patients. Semin Dial 33:316\u2013321. https:\/\/doi.org\/10.1111\/sdi.12888","journal-title":"Semin Dial"},{"key":"2933_CR26","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/ndt\/13.5.1226","volume":"13","author":"SA Harris","year":"1998","unstructured":"Harris SA, Brown EA (1998) Patients surviving more than 10 years on haemodialysis. The natural history of the complications of treatment. Nephrol Dial Transplant 13:1226\u20131233. https:\/\/doi.org\/10.1093\/ndt\/13.5.1226","journal-title":"Nephrol Dial Transplant"},{"key":"2933_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12882-020-02135-7","volume":"21","author":"ES Ferreira","year":"2020","unstructured":"Ferreira ES, Moreira TR, da Silva RG et al (2020) Survival and analysis of predictors of mortality in patients undergoing replacement renal therapy: a 20-year cohort. BMC Nephrol 21:502. https:\/\/doi.org\/10.1186\/s12882-020-02135-7","journal-title":"BMC Nephrol"},{"key":"2933_CR28","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.3390\/ijms21103422","volume":"21","author":"V Losappio","year":"2020","unstructured":"Losappio V, Franzin R, Infante B et al (2020) Molecular mechanisms of premature aging in hemodialysis: the complex interplay between innate and adaptive immune dysfunction. Int J Mol Sci 21:3422. https:\/\/doi.org\/10.3390\/ijms21103422","journal-title":"Int J Mol Sci"},{"key":"2933_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3081856","volume":"2017","author":"V Liakopoulos","year":"2017","unstructured":"Liakopoulos V, Roumeliotis S, Gorny X et al (2017) Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev 2017:3081856. https:\/\/doi.org\/10.1155\/2017\/3081856","journal-title":"Oxid Med Cell Longev"},{"key":"2933_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/ndt\/gfy272","volume":"34","author":"C Villain","year":"2019","unstructured":"Villain C, Ecochard R, Bouchet JL et al (2019) Relative prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities in elderly haemodialysis patients. Nephrol Dial Transplant 34:848\u2013858. https:\/\/doi.org\/10.1093\/ndt\/gfy272","journal-title":"Nephrol Dial Transplant"},{"key":"2933_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.15386\/cjmed-515","volume":"89","author":"D Moldovan","year":"2016","unstructured":"Moldovan D, Rusu C, Kacso IM et al (2016) Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis. Clujul Med 89:94\u2013103. https:\/\/doi.org\/10.15386\/cjmed-515","journal-title":"Clujul Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02933-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02933-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02933-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:51:22Z","timestamp":1767592282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02933-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2933"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02933-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7764761\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kosuke Ueda reported receiving honoraria from MSD K. K. Akinori Minato reported receiving honoraria from Astellas Pharma Inc, Merck Biopharma Co. Ltd., MSD K.K., and Janssen Pharmaceutical K.K. No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Review Committee of Kurume University School of Medicine (approval number: 23227) and the ethics committees of each participating institution. Given the retrospective nature of the study, informed consent was obtained via an opt-out mechanism, as described on each institution\u2019s website. Clinical data were retrospectively collected from medical records and analyzed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}